28 August 2025 - Negotiations between the UK Government and the pharmaceutical industry have ended without an agreement on changes to the medicines payment scheme.

ABPI, the UK pharma trade group, has argued that the current Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG) is in crisis because it imposes an “extremely high payment rate” on companies. The government raised the payment rate to 23.5% of revenues in December, exceeding the 15.9% expected by the industry and the single-digit rates used in countries such as France and Germany.

Read RAPS article